255 related articles for article (PubMed ID: 19517066)
1. Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
Ohba S; Hirose Y; Kawase T; Sano H
J Neurooncol; 2009 Dec; 95(3):307-316. PubMed ID: 19517066
[TBL] [Abstract][Full Text] [Related]
2. Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.
Hirose Y; Katayama M; Berger MS; Pieper RO
J Neurosurg; 2004 Jun; 100(6):1060-5. PubMed ID: 15200121
[TBL] [Abstract][Full Text] [Related]
3. The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Hayashi T; Adachi K; Ohba S; Hirose Y
J Neurooncol; 2013 Nov; 115(2):169-78. PubMed ID: 23943501
[TBL] [Abstract][Full Text] [Related]
4. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
Hirose Y; Berger MS; Pieper RO
Cancer Res; 2001 Aug; 61(15):5843-9. PubMed ID: 11479224
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of JNK potentiates temozolomide-induced cytotoxicity in U87MG glioblastoma cells via suppression of Akt phosphorylation.
Vo VA; Lee JW; Lee HJ; Chun W; Lim SY; Kim SS
Anticancer Res; 2014 Oct; 34(10):5509-15. PubMed ID: 25275048
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of invadopodia formation in temozolomide-resistant or adopted glioma is regulated by c-Jun terminal kinase-paxillin axis.
Ueno H; Tomiyama A; Yamaguchi H; Uekita T; Shirakihara T; Nakashima K; Otani N; Wada K; Sakai R; Arai H; Mori K
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):240-7. PubMed ID: 26518652
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells.
Filippi-Chiela EC; Thomé MP; Bueno e Silva MM; Pelegrini AL; Ledur PF; Garicochea B; Zamin LL; Lenz G
BMC Cancer; 2013 Mar; 13():147. PubMed ID: 23522185
[TBL] [Abstract][Full Text] [Related]
8. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
9. The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Chen PH; Cheng CH; Shih CM; Ho KH; Lin CW; Lee CC; Liu AJ; Chang CK; Chen KC
PLoS One; 2016; 11(11):e0167096. PubMed ID: 27893811
[TBL] [Abstract][Full Text] [Related]
10. The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Chen PH; Shen WL; Shih CM; Ho KH; Cheng CH; Lin CW; Lee CC; Liu AJ; Chen KC
Neuropharmacology; 2017 Apr; 116():300-314. PubMed ID: 27986595
[TBL] [Abstract][Full Text] [Related]
11. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence.
Hirose Y; Katayama M; Mirzoeva OK; Berger MS; Pieper RO
Cancer Res; 2005 Jun; 65(11):4861-9. PubMed ID: 15930307
[TBL] [Abstract][Full Text] [Related]
12. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
Hirose Y; Berger MS; Pieper RO
Cancer Res; 2001 Mar; 61(5):1957-63. PubMed ID: 11280752
[TBL] [Abstract][Full Text] [Related]
13. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Tang JB; Svilar D; Trivedi RN; Wang XH; Goellner EM; Moore B; Hamilton RL; Banze LA; Brown AR; Sobol RW
Neuro Oncol; 2011 May; 13(5):471-86. PubMed ID: 21377995
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression.
Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z
Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760
[TBL] [Abstract][Full Text] [Related]
15. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
16. Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.
Gramatzki D; Herrmann C; Happold C; Becker KA; Gulbins E; Weller M; Tabatabai G
PLoS One; 2013; 8(5):e63527. PubMed ID: 23667632
[TBL] [Abstract][Full Text] [Related]
17. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
[TBL] [Abstract][Full Text] [Related]
18. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
He Y; Kaina B
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells.
Tsuno T; Natsume A; Katsumata S; Mizuno M; Fujita M; Osawa H; Nakahara N; Wakabayashi T; Satoh Y; Inagaki M; Yoshida J
J Neurooncol; 2007 Jul; 83(3):249-58. PubMed ID: 17570035
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Liu XY; Zhang L; Wu J; Zhou L; Ren YJ; Yang WQ; Ming ZJ; Chen B; Wang J; Zhang Y; Yang JM
PLoS One; 2013; 8(11):e81345. PubMed ID: 24303044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
